The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updating data about a first-line modified schedule of gemcitabine with a lower dose than standard in very elderly or PS 2 patients with advanced non-small cell lung cancer.
A. Nacci
No relevant relationships to disclose
D. Galetta
No relevant relationships to disclose
E. Mazzoni
No relevant relationships to disclose
P. Rizzo
No relevant relationships to disclose
N. Calvani
No relevant relationships to disclose
L. Orlando
No relevant relationships to disclose
F. Sponziello
No relevant relationships to disclose
P. Schiavone
No relevant relationships to disclose
P. Fedele
No relevant relationships to disclose
C. Chetri
No relevant relationships to disclose
M. D' Amico
No relevant relationships to disclose
A. Marino
No relevant relationships to disclose
M. Cinefra
No relevant relationships to disclose
M. Criscuolo
No relevant relationships to disclose
S. Cinieri
No relevant relationships to disclose